Trinity Biotech
TRIB
74 hedge funds and large institutions have $318M invested in Trinity Biotech in 2013 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 8 closing their positions.
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
45% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 20
27% more capital invested
Capital invested by funds: $251M → $318M (+$66.6M)
26% more call options, than puts
Call options by funds: $885K | Put options by funds: $704K
7% more funds holding
Funds holding: 69 → 74 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.8M |
| 2 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$7.8M |
| 3 |
PC
Pier Capital
Stamford,
Connecticut
|
+$6.72M |
| 4 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$3.52M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$4.57M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.11M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.91M |
| 4 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$2.43M |
| 5 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$2.14M |
TRIB Hedge Fund Activity: Q4 2013 in Review
74 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2013, worth a combined $318M — up 27% from $251M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TRIB positions and 8 closed out — a net gain of 6 holders — while 29 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $14.8M. The largest seller was William Blair & Company, cutting an estimated $4.57M.
- 74 institutional investors held Trinity Biotech (TRIB) as of Q4 2013, up from 69 in Q3 2013.
- Funds reported $318M of Trinity Biotech stock for Q4 2013, up 27% quarter-over-quarter.
- 14 funds opened new Trinity Biotech positions in Q4 2013 and 8 closed out, a net change of +6 holders.
- The largest Trinity Biotech buyer in Q4 2013 was Fidelity Investments, an estimated $14.8M added.
- The largest Trinity Biotech seller in Q4 2013 was William Blair & Company, an estimated $4.57M sold.
Based on aggregated 13F filings for Q4 2013.